Higuchi Akira, Toriniwa Hiroko, Komiya Tomoyoshi, Nakayama Tetsuo
Kitasato-Daiichi Sankyo Vaccine, Division of Vaccine Production, Kitamoto City, Saitama Prefecture, 364-0026, Japan.
Kitasato-Daiichi Sankyo Vaccine, Division of Vaccine Development, Kitamoto City, Saitama Prefecture, 364-0026, Japan.
PLoS One. 2016 Mar 1;11(3):e0150213. doi: 10.1371/journal.pone.0150213. eCollection 2016.
An inactivated Japanese encephalitis virus (JEV) vaccine, which induces neutralizing antibodies, has been used for many years in Japan. In the present study, the JEV prM-E protein gene was cloned, inserted at the P/M junction of measles AIK-C cDNA, and an infectious virus was recovered. The JEV E protein was expressed in B95a cells infected with the recombinant virus. Cotton rats were inoculated with recombinant virus. Measles PA antibodies were detected three weeks after immunization. Neutralizing antibodies against JEV developed one week after inoculation, and EIA antibodies were detected three weeks after immunization. The measles AIK-C-based recombinant virus simultaneously induced measles and JEV immune responses, and may be a candidate for infant vaccines. Therefore, the present strategy of recombinant viruses based on a measles vaccine vector would be applicable to the platform for vaccine development.
一种能诱导中和抗体的灭活日本脑炎病毒(JEV)疫苗在日本已使用多年。在本研究中,JEV prM - E蛋白基因被克隆,插入到麻疹AIK - C cDNA的P/M连接处,并获得了一种感染性病毒。JEV E蛋白在感染重组病毒的B95a细胞中表达。用重组病毒接种棉鼠。免疫三周后检测到麻疹PA抗体。接种一周后产生针对JEV的中和抗体,免疫三周后检测到EIA抗体。基于麻疹AIK - C的重组病毒同时诱导麻疹和JEV免疫反应,可能是婴儿疫苗的候选者。因此,基于麻疹疫苗载体的重组病毒的当前策略将适用于疫苗开发平台。